High Frequency of Tc22 and Th22 Cells in Myasthenia Gravis Patients and Their Significant Reduction after Thymectomy

Robat-Jazi, Behrouz; Hosseini, Mina; Shaygannejad, Vahid; Nafissi, Shahriar; Rezaei, Abbas; Mansourain, Marjan; Mirmosayyeb, Omid; Esmaeil, Nafiseh

doi:10.1159/000490855

Cited by 10 publications

(10 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is thought that its efficacy is based on the removal of ectopic germinal centers and local pathogenic cells that drive the production of anti-AChR autoantibodies [ 20 ]. In our study, the signature populations rebounded in the blood after surgical removal of the inflammatory niche supporting the notion of pathological inflammatory leukocyte retention in the thymus during MG. Robat-Jazi and colleagues found significantly decreased IL-22 + Th cells in the blood of MG patients after thymectomy (compared to before thymectomy) [ 35 ], which is in accordance with our results of reduced IL-22 production by Th CD103 cells after removal of the thymus.…”

Section: Discussionsupporting

confidence: 92%

Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signature

et al. 2021

View full text Add to dashboard Cite

Myasthenia gravis (MG) is an autoimmune disease characterized by impaired neuromuscular signaling due to autoantibodies targeting the acetylcholine receptor. Although its auto-antigens and effector mechanisms are well defined, the cellular and molecular drivers underpinning MG remain elusive. Here, we employed high-dimensional single-cell mass and spectral cytometry of blood and thymus samples from MG patients in combination with supervised and unsupervised machine-learning tools to gain insight into the immune dysregulation underlying MG. By creating a comprehensive immune map, we identified two dysregulated subsets of inflammatory circulating memory T helper (Th) cells. These signature ThCD103 and ThGM cells populated the diseased thymus, were reduced in the blood of MG patients, and were inversely correlated with disease severity. Both signature Th subsets rebounded in the blood of MG patients after surgical thymus removal, indicative of their role as cellular markers of disease activity. Together, this in-depth analysis of the immune landscape of MG provides valuable insight into disease pathogenesis, suggests novel biomarkers and identifies new potential therapeutic targets for treatment.

show abstract

Section: Discussionsupporting

confidence: 92%

Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signature

et al. 2021

View full text Add to dashboard Cite

show abstract

“…They also showed a higher IL‐22 gene expression in patients with MG, which is consistent with a prior study 65 . Moreover, it has been shown that the frequency of Tc22 cells was elevated in MG patients compared to healthy controls, and this Tc22 frequency has been reduced significantly within 6 months of thymectomy 64 . The Th22/Tc22 ratio was significantly lower in MG patients than in the controls.…”

Section: Th22 In Autoimmune Disorderssupporting

confidence: 88%

Features and roles of T helper 22 cells in immunological diseases and malignancies

et al. 2021

View full text Add to dashboard Cite

T helper 22 (Th22) cell populations are a newly identified subset of CD4+ T cells that primarily mediate biological effects on the epithelial barrier through interleukin (IL)‐22. Although, new studies showed that both Th22 and IL‐22 are closely associated with the pathogenesis of inflammatory, autoimmune and allergic disease as well as malignancies. In this review, we aim to describe the development and characteristics of Th22 cells as well as their roles in the immunopathogenesis of immune‐related disorders and cancer.

show abstract

“…The frequency of Th22 cells in patients treated with TE was not significantly different from that of the healthy controls. After TE surgery, the frequency of Th22 cells was significantly reduced ( 93 ). Studies have also shown that the levels of IL-17 mRNA in PBMC and IL-17 concentrations in serum increase while levels of IL-22 mRNA and serum IL-22 decrease in MG patients.…”

Section: Th22 Cells In Autoimmune Diseasesmentioning

confidence: 99%

Role of Th22 Cells in the Pathogenesis of Autoimmune Diseases

et al. 2021

View full text Add to dashboard Cite

Upon antigenic stimulation, naïve CD4+T cells differentiate into different subsets and secrete various cytokines to exert biological effects. Th22 cells, a newly identified CD4+T cell subset,are distinct from the Th1, Th2 and Th17 subsets. Th22 cells secrete certain cytokines such as IL-22, IL-13 and TNF-α, but not others, such as IL-17, IL-4, or interferon-γ (IFN-γ), and they express chemokine receptors CCR4, CCR6 and CCR10. Th22 cells were initially found to play a role in skin inflammatory diseases, but recent studies have demonstrated their involvement in the development of various autoimmune diseases. Here, we review research advances in the origin, characteristics and effector mechanisms of Th22 cells, with an emphasis on the role of Th22 cells and their main effector cytokine IL-22 in the pathogenesis of autoimmune diseases. The findings presented here may facilitate the development of new therapeutic strategies for targeting these diseases.

show abstract

High Frequency of Tc22 and Th22 Cells in Myasthenia Gravis Patients and Their Significant Reduction after Thymectomy

Cited by 10 publications

References 61 publications

Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signature

Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signature

Features and roles of T helper 22 cells in immunological diseases and malignancies

Role of Th22 Cells in the Pathogenesis of Autoimmune Diseases

Contact Info

Product

Resources

About